|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111).
|
23934175 |
2013 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Trisomy of chromosome 7 in IDH mutated astrocytoma and PTEN mutations in IDH mutated oligodendroglioma are potential markers of poor prognosis, but require confirmation in larger series.
|
29663171 |
2018 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The DSC-MRI procedure may provide insight into the IDH1/2 mutation and ATRX expression status and MGMT methylation profile of diffuse glioma; however, taking integrated oligodendroglioma into account limits the diagnostic performance of rCBV in non-invasively predicting the molecular subtype.
|
29468261 |
2019 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both 1p19q codeletion and IDH-1 mutation predict outcome of patients with both oligodendroglioma and AO.
|
22396073 |
2012 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Distinct spectral profiles were observed for lesions with IDH-mutated genotypes, between astrocytoma and oligodendroglioma histologies, as well as for tumors that had undergone MP.
|
28327577 |
2017 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One hundred twenty-six tumors could be classified: 20 as type II (IDH mutation [mut], "astrocytoma"), 49 as type I (1p/19q codeletion, "oligodendroglioma"), 55 as type III (7+/10q- or TERTmut and 1p/19q intact, "glioblastoma"), and 2 as childhood glioblastoma (H3F3Amut), leaving 7 unclassified (total 91% classified).
|
26354927 |
2016 |
|
Adult Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
|
20160062 |
2010 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Secondly, when analyzed in molecular subgroups, we were similarly unable to detect a significant PFS or OS benefit in IDH MT/codel subgroup (N = 269; HR 1.47; 95% CI 0.92-2.34; P = 0.11 and HR 1.54; 95% CI 0.78-3.05; P = 0.21, respectively), oligodendroglioma with IDH MT/codel subgroup (N = 233; HR 1.33; 95% CI 0.79-2.21; P = 0.28 and HR 1.16; 95% CI 0.53-2.54; P = 0.70, respectively) or other relevant subgroups.
|
30206763 |
2018 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The oligodendroglioma model presented here is a valuable model for further functional elucidation of the effects of IDH1 mutations on tumor metabolism and may aid in the rational development of novel therapeutic strategies for the large subgroup of gliomas carrying IDH1 mutations.
|
24252742 |
2013 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A c.515G>T (p.R172M) mutation of the IDH2 gene was only identified in a grade II oligodendroglioma patient which was wild-type for IDH1.
|
21643842 |
2011 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The EMP3 and MGMT promoter methylation was more frequent in OII than in GBM patients, and the IDH1 mutation was absent in GBM.
|
22992787 |
2012 |
|
Adult Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patient KK was a 68-yr-old female who was found to have a large, left-sided insular mass that was shown to be an oligodendroglioma WHO grade II, positive for codeletion 1p/19q and IDH1 mutant on biopsy.
|
31058967 |
2020 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with IDH wild type anaplastic astrocytoma and glioblastoma had a significantly shorter median PFS (19.3 months vs. NR, p = 0.001) and median OS (43.5 months vs NR, p = 0.007) than those with IDH mutated grade III anaplastic astrocytoma and oligodendroglioma.
|
31371189 |
2019 |
|
Adult Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Diffuse gliomas can be separated in astrocytoma and oligodendroglioma based on IDH1/2, ATRX, and TP53 mutational status.
|
31714292 |
2020 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Indeed, 1p36/19q13 has been shown successively to predict increased chemosensitivity and better prognosis, to be associated with frontal location in brain and classic oligodendroglioma morphology, to be mutually exclusive with high-level gene amplification, to be actually whole chromosome arms 1p/19q codeletion, to mediate a t(1;19)(q10;p10) and to be associated with IDH mutations.
|
22913971 |
2012 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The mutation analysis performed on the latter case with DNA separately sampled from the oligodendroglioma- like area and the astrocytoma-like area detected IDH1 G395A in both areas.
|
22385787 |
2012 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The reported two cases were initially diagnosed as oligodendroglioma with 1p/19q-codeletion and mutation of <i>isocitrate dehydrogenase 1 (IDH1)</i>-R132H.
|
31508376 |
2019 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 135 cases consisted of 38 IDH-mutant [17 astrocytoma (AC), 13 oligodendroglioma (OD) and eight glioblastoma (GBM)], 87 IDH-wildtype (six AC, three OD and 78 GBM), and 10 diffuse midline glioma, H3K27M-mutant.
|
30710203 |
2019 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analyzed markers, including IDH mutation(IDHmut), 1p19q codeletion(1p19qcodel), ATRX expression loss(ATRX loss) and p53 overexpression, and outcomes in 159 patients with WHO grade II oligodendroglioma, oligoastrocytoma, and astrocytoma (2003-2012).
|
26210286 |
2015 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We first compared tumor tissues (TT) and minimally infiltrated parenchymal tissues (MIT) of four IDH1-mutated oligodendrogliomas to verify whether proteins specific to oligodendroglioma tumor cells could be identified from one patient to another.
|
21898821 |
2011 |
|
Adult Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the aberration profiles of IDH1 and BRAF suggest that the oligodendroglioma arose independent of cerebellar pilocytic astrocytoma.
|
23082883 |
2013 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Triple-positive (IDH1 and TERT mutation with 1p19q codeletion) glioma tended to be oligodendroglioma present with much better clinical outcome compared to TERT mutation only group who is glioblastoma inclined (median overall survival 39 months VS 18 months).
|
28915860 |
2017 |
|
Adult Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, identification of a common IDH1 mutation in enchondroma and oligodendroglioma-matched pair specimens supports the hypothesis that IDH1/2 mosaicism initiates tumorigenesis.
|
29224049 |
2018 |
|
Adult Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the 2016 WHO classification, the diagnosis of oligodendroglioma has been restricted to IDH mutated, 1p19q codeleted tumors (IDHmut-codel).
|
29186201 |
2017 |
|
Adult Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second.
|
29077933 |
2018 |